Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.83), $0.03 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.